These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 22732108)

  • 1. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.
    Irace C; De Luca S; Shehaj E; Carallo C; Loprete A; Scavelli F; Gnasso A
    Diab Vasc Dis Res; 2013 Jan; 10(1):72-7. PubMed ID: 22732108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
    Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
    Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
    Reuter H; Erdmann E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):571-4. PubMed ID: 17342635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
    Smits MM; Tonneijck L; Muskiet MH; Hoekstra T; Kramer MH; Diamant M; van Raalte DH
    Eur J Endocrinol; 2017 Jan; 176(1):77-86. PubMed ID: 27777261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of pioglitazone and metformin on vascular endothelial function in patients with type 2 diabetes treated with sulfonylureas.
    Naka KK; Papathanassiou K; Bechlioulis A; Pappas K; Kazakos N; Kanioglou C; Kostoula A; Vezyraki P; Makriyiannis D; Tsatsoulis A; Michalis LK
    Diab Vasc Dis Res; 2012 Jan; 9(1):52-8. PubMed ID: 22049096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers.
    Gurkan E; Tarkun I; Sahin T; Cetinarslan B; Canturk Z
    Diabetes Res Clin Pract; 2014 Dec; 106(3):567-75. PubMed ID: 25458329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus.
    Torimoto K; Okada Y; Mori H; Otsuka T; Kawaguchi M; Matsuda M; Kuno F; Sugai K; Sonoda S; Hajime M; Tanaka K; Arao T; Tanaka Y
    Cardiovasc Diabetol; 2015 Feb; 14():25. PubMed ID: 25849903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelial function in patients with newly diagnosed type 2 diabetes receiving early intensive insulin therapy.
    Tian J; Wang J; Li Y; Villarreal D; Carhart R; Dong Y; Wen Y; Liu K
    Am J Hypertens; 2012 Dec; 25(12):1242-8. PubMed ID: 22895449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.
    Scalzo RL; Moreau KL; Ozemek C; Herlache L; McMillin S; Gilligan S; Huebschmann AG; Bauer TA; Dorosz J; Reusch JE; Regensteiner JG
    J Diabetes Complications; 2017 Feb; 31(2):449-455. PubMed ID: 27884660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans.
    Koska J; Sands M; Burciu C; D'Souza KM; Raravikar K; Liu J; Truran S; Franco DA; Schwartz EA; Schwenke DC; D'Alessio D; Migrino RQ; Reaven PD
    Diabetes; 2015 Jul; 64(7):2624-35. PubMed ID: 25720388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
    Nyström T; Gutniak MK; Zhang Q; Zhang F; Holst JJ; Ahrén B; Sjöholm A
    Am J Physiol Endocrinol Metab; 2004 Dec; 287(6):E1209-15. PubMed ID: 15353407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired flow-mediated vasodilation in type 2 diabetes: lack of relation to microvascular dysfunction.
    Meyer MF; Lieps D; Schatz H; Pfohl M
    Microvasc Res; 2008 May; 76(1):61-5. PubMed ID: 18448131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.
    Papathanassiou K; Naka KK; Kazakos N; Kanioglou C; Makriyiannis D; Pappas K; Katsouras CS; Liveris K; Kolettis T; Tsatsoulis A; Michalis LK
    Atherosclerosis; 2009 Jul; 205(1):221-6. PubMed ID: 19135671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
    Kelly AS; Bergenstal RM; Gonzalez-Campoy JM; Katz H; Bank AJ
    Cardiovasc Diabetol; 2012 Jun; 11():64. PubMed ID: 22681705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of 6 months glucagon-like peptide-1 receptor agonist treatment on endothelial function in type 2 diabetes mellitus patients.
    Hopkins ND; Cuthbertson DJ; Kemp GJ; Pugh C; Green DJ; Cable NT; Jones H
    Diabetes Obes Metab; 2013 Aug; 15(8):770-3. PubMed ID: 23451821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).
    Goldfine AB; Buck JS; Desouza C; Fonseca V; Chen YD; Shoelson SE; Jablonski KA; Creager MA;
    Diabetes Care; 2013 Dec; 36(12):4132-9. PubMed ID: 24130358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow-mediated dilatation of the brachial artery is a poorly reproducible indicator of microvascular function in Type I diabetes mellitus.
    Hamilton P; Lockhart CJ; McCann AJ; Agnew CE; Harbinson MT; McClenaghan V; Bleakley C; McGivern RC; McVeigh G
    QJM; 2011 Jul; 104(7):589-97. PubMed ID: 21421993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.